These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14534393)

  • 1. A qualitative investigation of antiretroviral therapy among injection drug users.
    Pach A; Cerbone FG; Gerstein DR
    AIDS Behav; 2003 Mar; 7(1):87-100. PubMed ID: 14534393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV testing and treatment among at-risk drinking injection drug users.
    Arasteh K; Des Jarlais DC
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(3):196-201. PubMed ID: 19414827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis.
    Werb D; Mills EJ; Montaner JS; Wood E
    Lancet Infect Dis; 2010 Jul; 10(7):464-9. PubMed ID: 20610328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users.
    Ding L; Landon BE; Wilson IB; Wong MD; Shapiro MF; Cleary PD
    Arch Intern Med; 2005 Mar; 165(6):618-23. PubMed ID: 15795336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group.
    Carrieri MP; Moatti JP; Vlahov D; Obadia Y; Reynaud-Maurupt C; Chesney M
    J Epidemiol Community Health; 1999 Jan; 53(1):4-8. PubMed ID: 10326045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users.
    Mann B; Milloy MJ; Kerr T; Zhang R; Montaner J; Wood E
    HIV Med; 2012 Nov; 13(10):596-601. PubMed ID: 22551168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV seropositivity was related to HBsAg seropositivity among injecting drug users in Taiwan.
    Hsieh MH; Hsieh MY; Huang CF; Yeh ML; Wang SC; Yang JF; Chang K; Lin WR; Lin CY; Chen TC; Huang JF; Dai CY; Tsai JJ; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2016 Feb; 32(2):96-102. PubMed ID: 26944329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
    Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G;
    MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
    Celentano DD; Galai N; Sethi AK; Shah NG; Strathdee SA; Vlahov D; Gallant JE
    AIDS; 2001 Sep; 15(13):1707-15. PubMed ID: 11546947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication therapy among intravenous drug users (IDUs) with HIV infection.
    Smith PC; Page JB
    AIDS Patient Care STDS; 1996 Apr; 10(2):101-10. PubMed ID: 11361686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities.
    Remien RH; Hirky AE; Johnson MO; Weinhardt LS; Whittier D; Le GM
    AIDS Behav; 2003 Mar; 7(1):61-72. PubMed ID: 14534391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demographic characteristics, treatment history, drug risk behaviors, and condom use attitudes for U.S. and Russian injection drug users: the need for targeted sexual risk behavior interventions.
    Ksobiech K; Somlai AM; Kelly JA; Gore-Felton C; Benotsch E; McAuliffe T; Hackl K; Ostrovski D; Kozlov AP
    AIDS Behav; 2005 Mar; 9(1):111-20. PubMed ID: 15812618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.
    Weber R; Huber M; Rickenbach M; Furrer H; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Ledergerber B;
    HIV Med; 2009 Aug; 10(7):407-16. PubMed ID: 19490174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: latent class analysis.
    Keiser O; Spycher B; Rauch A; Calmy A; Cavassini M; Glass TR; Nicca D; Ledergerber B; Egger M;
    AIDS Behav; 2012 Feb; 16(2):245-55. PubMed ID: 21630013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral interventions for HIV-positive and HCV-positive drug users.
    Strathdee SA; Patterson TL
    AIDS Behav; 2006 Mar; 10(2):115-30. PubMed ID: 16463006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.